No Data
No Data
Baihua Pharmaceutical (600721.SH) announced 2023 annual results with net profit of 129.723 million yuan, turning a year-on-year loss into profit
According to the Zhitong Finance App, Baihua Pharmaceutical (600721.SH) disclosed its 2023 annual report. The company achieved operating revenue of 369 million yuan during the reporting period, an increase of 5.54% over the previous year. Net profit attributable to shareholders of listed companies was 129.723 million yuan, and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 10.729 million yuan, turning losses into profits over the previous year. Basic earnings per share were 0.0342 yuan/share.
Baihua Pharmaceutical (600721.SH): Does not involve AI technology
Gelonghui, March 26 | Baihua Pharmaceutical (600721.SH) said on the interactive platform that the company mainly provides customers with one-stop outsourcing and technological achievement transformation services for the whole process from drug discovery, pharmaceutical chemical component development, clinical trials and registration, without involving AI technology.
Baihua Pharmaceutical (600721.SH): Currently no overseas business
Gelonghui, Feb. 19 | Baihua Pharmaceutical (600721.SH) said on an interactive platform that the company currently has no overseas business. For specific revenue, please pay attention to the company's 2023 annual report.
Baihua Pharmaceutical (600721.SH): Expected net profit of 12.5 million yuan to 16.5 million yuan in 2023, turning a year-on-year loss into profit
Gelonghui, January 25 | Baihua Pharmaceutical (600721.SH) announced that according to preliminary estimates by the finance department, it is estimated that net profit attributable to the owner of the parent company in 2023 will be 12.5 million yuan to 16.5 million yuan. Compared with the same period last year, it will turn a loss into a profit. In 2023, net profit attributable to owners of the parent company after deducting non-recurring profit and loss is expected to be between RMB 10.5 million and RMB 14.5 million. The company actively expanded the market and signed an increase in new orders, while strengthening the control of project progress and R&D efficiency. The project R&D cycle was shortened during the reporting period, fixed costs were diluted, and the cost rate was reduced
Baihua Pharmaceutical (600721.SH)'s financial results and net profit for the first three quarters of the release were 17.69 million yuan, up 60.90% year-on-year
Baihua Pharmaceutical (600721.SH) disclosed its report for the third quarter of 2023. The company achieved operating income during the reporting period...
[Instant Analysis of BT Financial Report] Baihua Pharmaceutical's 2023 Interim Report: Net profit increased by 26.28%, gross margin increased, and performance was steady
Baihua Pharmaceutical (stock code: 600721) is a company focusing on the field of generic pharmaceuticals. Its main business covers a full range of drug development and technical services such as drug discovery, pharmaceutical chemical ingredient production and control development, clinical trials, and registration. In the generic drug market in China, Baihua Pharmaceutical occupies an important position and is committed to meeting the aging population and the growing health needs of citizens. According to Baihua Pharmaceutical's 2023 interim report, the company's total asset balance at the end of the period was 1,025 million yuan, a slight increase from 1,001 billion yuan at the beginning of the period. The total closing balance of liabilities was $337 million, compared to 3.3 million at the beginning of the period
No Data